Cargando…

A global study of the unmet need for glycemic control and predictor factors among patients with type 2 diabetes mellitus who have achieved optimal fasting plasma glucose control on basal insulin

BACKGROUND: This study used data from different sources to identify the extent of the unmet need for postprandial glycemic control in patients with type 2 diabetes mellitus (T2DM) after the initiation of basal insulin therapy in Europe, Asia Pacific, the United States, and Latin America. METHODS: Di...

Descripción completa

Detalles Bibliográficos
Autores principales: Raccah, Denis, Chou, Engels, Colagiuri, Stephen, Gaàl, Zsolt, Lavalle, Fernando, Mkrtumyan, Ashot, Nikonova, Elena, Tentolouris, Nikolaos, Vidal, Josep, Davies, Melanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347910/
https://www.ncbi.nlm.nih.gov/pubmed/27606888
http://dx.doi.org/10.1002/dmrr.2858
_version_ 1782514137536921600
author Raccah, Denis
Chou, Engels
Colagiuri, Stephen
Gaàl, Zsolt
Lavalle, Fernando
Mkrtumyan, Ashot
Nikonova, Elena
Tentolouris, Nikolaos
Vidal, Josep
Davies, Melanie
author_facet Raccah, Denis
Chou, Engels
Colagiuri, Stephen
Gaàl, Zsolt
Lavalle, Fernando
Mkrtumyan, Ashot
Nikonova, Elena
Tentolouris, Nikolaos
Vidal, Josep
Davies, Melanie
author_sort Raccah, Denis
collection PubMed
description BACKGROUND: This study used data from different sources to identify the extent of the unmet need for postprandial glycemic control in patients with type 2 diabetes mellitus (T2DM) after the initiation of basal insulin therapy in Europe, Asia Pacific, the United States, and Latin America. METHODS: Different levels of evidence were used as available for each country/region, with data extracted from seven randomized controlled trials (RCTs), three clinical trial registries (CTRs), and three electronic medical record (EMR) databases. Glycemic status was categorized as “well controlled” (glycated hemoglobin [HbA(1c)] at target [<7%]), “residual hyperglycemia” (fasting plasma glucose [FPG] but not HbA(1c) at target [FPG <7.2/7.8 mmol/L, <130/140 mg/dL, depending on country‐specific recommendations]), or “uncontrolled” (both FPG and HbA(1c) above target). Predictor factors were identified from the RCT data set using logistic regression analysis. RESULTS: RCT data showed that 16.9% to 28.0%, 42.7% to 54.4%, and 16.9% to 38.1% of patients with T2DM had well‐controlled glycemia, residual hyperglycemia, and uncontrolled hyperglycemia, respectively. In CTRs, respective ranges were 21.8% to 33.6%, 31.5% to 35.6%, and 30.7% to 46.8%, and in EMR databases were 4.4% to 21.0%, 23.9% to 31.8%, and 53.6% to 63.8%. Significant predictor factors of residual hyperglycemia identified from RCT data included high baseline HbA(1c) (all countries/regions except Brazil), high baseline FPG (United Kingdom/Japan), longer duration of diabetes (Brazil), and female sex (Europe/Latin America). CONCLUSIONS: Irrespective of intrinsic differences between data sources, 24% to 54% of patients with T2DM globally had residual hyperglycemia with HbA(1c) not at target, despite achieving FPG control, indicating a significant unmet need for postprandial glycemic control.
format Online
Article
Text
id pubmed-5347910
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-53479102017-03-23 A global study of the unmet need for glycemic control and predictor factors among patients with type 2 diabetes mellitus who have achieved optimal fasting plasma glucose control on basal insulin Raccah, Denis Chou, Engels Colagiuri, Stephen Gaàl, Zsolt Lavalle, Fernando Mkrtumyan, Ashot Nikonova, Elena Tentolouris, Nikolaos Vidal, Josep Davies, Melanie Diabetes Metab Res Rev Research Articles BACKGROUND: This study used data from different sources to identify the extent of the unmet need for postprandial glycemic control in patients with type 2 diabetes mellitus (T2DM) after the initiation of basal insulin therapy in Europe, Asia Pacific, the United States, and Latin America. METHODS: Different levels of evidence were used as available for each country/region, with data extracted from seven randomized controlled trials (RCTs), three clinical trial registries (CTRs), and three electronic medical record (EMR) databases. Glycemic status was categorized as “well controlled” (glycated hemoglobin [HbA(1c)] at target [<7%]), “residual hyperglycemia” (fasting plasma glucose [FPG] but not HbA(1c) at target [FPG <7.2/7.8 mmol/L, <130/140 mg/dL, depending on country‐specific recommendations]), or “uncontrolled” (both FPG and HbA(1c) above target). Predictor factors were identified from the RCT data set using logistic regression analysis. RESULTS: RCT data showed that 16.9% to 28.0%, 42.7% to 54.4%, and 16.9% to 38.1% of patients with T2DM had well‐controlled glycemia, residual hyperglycemia, and uncontrolled hyperglycemia, respectively. In CTRs, respective ranges were 21.8% to 33.6%, 31.5% to 35.6%, and 30.7% to 46.8%, and in EMR databases were 4.4% to 21.0%, 23.9% to 31.8%, and 53.6% to 63.8%. Significant predictor factors of residual hyperglycemia identified from RCT data included high baseline HbA(1c) (all countries/regions except Brazil), high baseline FPG (United Kingdom/Japan), longer duration of diabetes (Brazil), and female sex (Europe/Latin America). CONCLUSIONS: Irrespective of intrinsic differences between data sources, 24% to 54% of patients with T2DM globally had residual hyperglycemia with HbA(1c) not at target, despite achieving FPG control, indicating a significant unmet need for postprandial glycemic control. John Wiley and Sons Inc. 2016-10-13 2017-03 /pmc/articles/PMC5347910/ /pubmed/27606888 http://dx.doi.org/10.1002/dmrr.2858 Text en © 2016 The Authors. Diabetes/Metabolism Research and Reviews published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Research Articles
Raccah, Denis
Chou, Engels
Colagiuri, Stephen
Gaàl, Zsolt
Lavalle, Fernando
Mkrtumyan, Ashot
Nikonova, Elena
Tentolouris, Nikolaos
Vidal, Josep
Davies, Melanie
A global study of the unmet need for glycemic control and predictor factors among patients with type 2 diabetes mellitus who have achieved optimal fasting plasma glucose control on basal insulin
title A global study of the unmet need for glycemic control and predictor factors among patients with type 2 diabetes mellitus who have achieved optimal fasting plasma glucose control on basal insulin
title_full A global study of the unmet need for glycemic control and predictor factors among patients with type 2 diabetes mellitus who have achieved optimal fasting plasma glucose control on basal insulin
title_fullStr A global study of the unmet need for glycemic control and predictor factors among patients with type 2 diabetes mellitus who have achieved optimal fasting plasma glucose control on basal insulin
title_full_unstemmed A global study of the unmet need for glycemic control and predictor factors among patients with type 2 diabetes mellitus who have achieved optimal fasting plasma glucose control on basal insulin
title_short A global study of the unmet need for glycemic control and predictor factors among patients with type 2 diabetes mellitus who have achieved optimal fasting plasma glucose control on basal insulin
title_sort global study of the unmet need for glycemic control and predictor factors among patients with type 2 diabetes mellitus who have achieved optimal fasting plasma glucose control on basal insulin
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347910/
https://www.ncbi.nlm.nih.gov/pubmed/27606888
http://dx.doi.org/10.1002/dmrr.2858
work_keys_str_mv AT raccahdenis aglobalstudyoftheunmetneedforglycemiccontrolandpredictorfactorsamongpatientswithtype2diabetesmellituswhohaveachievedoptimalfastingplasmaglucosecontrolonbasalinsulin
AT chouengels aglobalstudyoftheunmetneedforglycemiccontrolandpredictorfactorsamongpatientswithtype2diabetesmellituswhohaveachievedoptimalfastingplasmaglucosecontrolonbasalinsulin
AT colagiuristephen aglobalstudyoftheunmetneedforglycemiccontrolandpredictorfactorsamongpatientswithtype2diabetesmellituswhohaveachievedoptimalfastingplasmaglucosecontrolonbasalinsulin
AT gaalzsolt aglobalstudyoftheunmetneedforglycemiccontrolandpredictorfactorsamongpatientswithtype2diabetesmellituswhohaveachievedoptimalfastingplasmaglucosecontrolonbasalinsulin
AT lavallefernando aglobalstudyoftheunmetneedforglycemiccontrolandpredictorfactorsamongpatientswithtype2diabetesmellituswhohaveachievedoptimalfastingplasmaglucosecontrolonbasalinsulin
AT mkrtumyanashot aglobalstudyoftheunmetneedforglycemiccontrolandpredictorfactorsamongpatientswithtype2diabetesmellituswhohaveachievedoptimalfastingplasmaglucosecontrolonbasalinsulin
AT nikonovaelena aglobalstudyoftheunmetneedforglycemiccontrolandpredictorfactorsamongpatientswithtype2diabetesmellituswhohaveachievedoptimalfastingplasmaglucosecontrolonbasalinsulin
AT tentolourisnikolaos aglobalstudyoftheunmetneedforglycemiccontrolandpredictorfactorsamongpatientswithtype2diabetesmellituswhohaveachievedoptimalfastingplasmaglucosecontrolonbasalinsulin
AT vidaljosep aglobalstudyoftheunmetneedforglycemiccontrolandpredictorfactorsamongpatientswithtype2diabetesmellituswhohaveachievedoptimalfastingplasmaglucosecontrolonbasalinsulin
AT daviesmelanie aglobalstudyoftheunmetneedforglycemiccontrolandpredictorfactorsamongpatientswithtype2diabetesmellituswhohaveachievedoptimalfastingplasmaglucosecontrolonbasalinsulin
AT raccahdenis globalstudyoftheunmetneedforglycemiccontrolandpredictorfactorsamongpatientswithtype2diabetesmellituswhohaveachievedoptimalfastingplasmaglucosecontrolonbasalinsulin
AT chouengels globalstudyoftheunmetneedforglycemiccontrolandpredictorfactorsamongpatientswithtype2diabetesmellituswhohaveachievedoptimalfastingplasmaglucosecontrolonbasalinsulin
AT colagiuristephen globalstudyoftheunmetneedforglycemiccontrolandpredictorfactorsamongpatientswithtype2diabetesmellituswhohaveachievedoptimalfastingplasmaglucosecontrolonbasalinsulin
AT gaalzsolt globalstudyoftheunmetneedforglycemiccontrolandpredictorfactorsamongpatientswithtype2diabetesmellituswhohaveachievedoptimalfastingplasmaglucosecontrolonbasalinsulin
AT lavallefernando globalstudyoftheunmetneedforglycemiccontrolandpredictorfactorsamongpatientswithtype2diabetesmellituswhohaveachievedoptimalfastingplasmaglucosecontrolonbasalinsulin
AT mkrtumyanashot globalstudyoftheunmetneedforglycemiccontrolandpredictorfactorsamongpatientswithtype2diabetesmellituswhohaveachievedoptimalfastingplasmaglucosecontrolonbasalinsulin
AT nikonovaelena globalstudyoftheunmetneedforglycemiccontrolandpredictorfactorsamongpatientswithtype2diabetesmellituswhohaveachievedoptimalfastingplasmaglucosecontrolonbasalinsulin
AT tentolourisnikolaos globalstudyoftheunmetneedforglycemiccontrolandpredictorfactorsamongpatientswithtype2diabetesmellituswhohaveachievedoptimalfastingplasmaglucosecontrolonbasalinsulin
AT vidaljosep globalstudyoftheunmetneedforglycemiccontrolandpredictorfactorsamongpatientswithtype2diabetesmellituswhohaveachievedoptimalfastingplasmaglucosecontrolonbasalinsulin
AT daviesmelanie globalstudyoftheunmetneedforglycemiccontrolandpredictorfactorsamongpatientswithtype2diabetesmellituswhohaveachievedoptimalfastingplasmaglucosecontrolonbasalinsulin